US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CAR-T Concept

1,732.48

+25.191.48%

Number of Gainers:2

Number of Losers:- -

Number of Flat:- -

PE:- -

High:1,752.01

Open:1,741.12

Low:1,727.26

Close:1,707.29

Volume:2.03M

Turnover:289.25M

Market Cap:446.51B

Float Cap:438.18B

Loading ...

Novartis, Alteogen Sign Drug-Technology Deal Worth Up to $3.2 Billion

MT Newswires Live

Is Gilead Sciences (GILD) Fully Valued On Its New HIV And Cancer Drug Approvals?

Simply Wall St.

Alteogen enters option, license agreement with Novartis

Novartis Trial Suspensions to Have Limited Financial Impact

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi

Novartis MS Trials Open Door to Multibillion-Dollar Sales Opportunity

Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials

Novartis AG Stock (NVS) Moved Up by 6.54% on Sep 1: Drivers Behind the Movement

Novartis's Multiple Sclerosis Trial Results Match Best Hopes

US Stock Alert: Novartis Gains 5% On Positive Late-Stage Trial Results For MS Oral Therapy

Novartis up Nearly 6%, on Pace for Largest Percent Increase Since March 2023

【US Pre-Market】US Futures and Chip Stocks Fall as Global Bond Sell-Off Deepens; Gold Drops Below $4,400, Brent Crude Tops $92

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Why Novartis Stock is Heading for Its Best Day Since 2023 After 3 Patient Deaths

Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

Novartis announces results from Phase III Remodel-1/-2 trials of remibrutinib

Novartis halts autoimmune CAR-T trials following three deaths, Reuters says

Novartis Says Remibrutinib Significantly Reduces Relapse Rates in Phase 3 Multiple Sclerosis Trials

MT Newswires Live

Novartis Faces Dual Outcomes: CAR-T Halted After Three Deaths While MS Drug Shows Late-Stage Promise

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/BK4578/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1732.4762,"timestamp":1789398951379,"preClose":1707.2908,"halted":0,"volume":2029813,"delay":0,"changeRate":0.014752,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":25.185425,"latestTime":"09-14 11:15:52 EDT","open":1741.1221,"high":1752.0092,"low":1727.2628,"amount":289253243.67881,"amplitude":0.014495,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":8.281713,"peRate":46.44356,"turnoverRate":0.000657,"increases":2,"decrements":0,"flats":0,"marketCap":446509629440,"floatMarketCap":438183542784},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1752.0092,"amplitude":0.014495,"preClose":1707.2908,"low":1727.2628,"pbRate":"8.281713","latestPrice":1732.4762,"volume":2029813,"delay":0,"open":1741.1221,"prevYearClose":1612.5378,"prevWeekClose":1707.2908,"prevMonthClose":1830.2803,"prevQuarterClose":1768.1697,"fiveDayClose":1911.2454,"twentyDayClose":1783.4272,"sixtyDayClose":1720.8374,"secType":"PLATE","market":"US","turnoverRate":0.000657,"peRate":46.44356,"marketCap":446509629440,"floatMarketCap":438183542784,"timestamp":1789398951379,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":2,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664162238","title":"Novartis, Alteogen Sign Drug-Technology Deal Worth Up to $3.2 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2664162238","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664162238?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:35","pubTimestamp":1788348951,"startTime":"0","endTime":"0","summary":"Novartis  has signed an option and licensing agreement with South Korean biotech Alteogen to develop and sell subcutaneous versions of multiple Novartis drugs using its ALT-B4 technology, Alteogen said Wednesday.The company said ALT-B4 is designed to convert biologic medicines typically given through intravenous infusions into faster injections under the skin.If Novartis exercises all options and all milestones are met, Alteogen could receive up to $3.223 billion, including option fees, development and commercial milestones, and royalties on product sales, it added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4578","IE0009355771.USD","IE00B4R5TH58.HKD","LU0211331839.USD","BK4585","IE0002141913.USD","MEDX","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","BK4007","LU0208291251.USD","NVS","PPH","IE00B2B36J28.USD","LU0320765489.SGD","IE00BFTCPJ56.SGD","BK4588","LU0070302665.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664381433","title":"Is Gilead Sciences (GILD) Fully Valued On Its New HIV And Cancer Drug Approvals?","url":"https://stock-news.laohu8.com/highlight/detail?id=2664381433","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664381433?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:23","pubTimestamp":1788348209,"startTime":"0","endTime":"0","summary":"Gilead Sciences (GILD) has drawn fresh investor attention after two recent regulatory decisions. The FDA approved Bixlenvo for virologically suppressed adults with HIV, and the European Commission cleared Trodelvy plus Keytruda for certain metastatic triple-negative breast cancer patients.\nThese approvals arrive after a strong run in Gilead Sciences' stock, with a 30-day share price return of 15.14% and a year-to-date share price return of 23.29%, alongside a 36.48% 1-year total shareholder...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/is-gilead-sciences-gild-fully-valued-on-its-new-hiv-and-canc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/is-gilead-sciences-gild-fully-valued-on-its-new-hiv-and-canc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","LU2089984988.USD","LU0859254822.USD","LU2324357040.USD","LU1066051498.USD","LU1778281490.HKD","LU0122379950.USD","LU1934455194.USD","LU1934455863.HKD","LU0289739699.SGD","IE0002270589.USD","IE00B7SZLL34.SGD","IBBQ","LU0965509283.SGD","SG9999015952.SGD","SG9999015986.USD","BIB","BK4585","BK4139","IE00B19Z3581.USD","LU1674673428.USD","LU0965509101.SGD","BK4532","TBXU","BMED","LU2112291526.USD","MEDI","LU0114720955.EUR","LU0823416689.USD","SG9999015978.USD","LU0109394709.USD","LU1585245621.USD","IE00B3T34201.USD","LU0889565916.HKD","IBB","LU1066053197.SGD","LU1674673691.USD","BBH","BK4566","BK4568","LU0882574055.USD","GILD","LU0058720904.USD","BK4578","IE00BZ1G4Q59.USD","TMED","LU2087621335.USD","LU1023059063.AUD","LU1061106388.HKD","LU1037948541.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664165388","title":"Alteogen enters option, license agreement with Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2664165388","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664165388?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:15","pubTimestamp":1788347740,"startTime":"0","endTime":"0","summary":"Alteogen announced that it has entered into an option and license agreement with Novartis (NVS) for the development and commercialization of subcut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alteogen-enters-option-license-agreement-with-novartis-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alteogen-enters-option-license-agreement-with-novartis-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVS","LU0070302665.USD","LU0211331839.USD","BK4588","MEDX","BK4585","IE0002141913.USD","BK4532","IE0009355771.USD","IE00BJJMRZ35.SGD","PPH","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0320765489.SGD","LU0208291251.USD","IE00B4R5TH58.HKD","BK4578","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664920892","title":"Novartis Trial Suspensions to Have Limited Financial Impact","url":"https://stock-news.laohu8.com/highlight/detail?id=2664920892","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664920892?lang=en_us&edition=fundamental","pubTime":"2026-09-02 16:15","pubTimestamp":1788336900,"startTime":"0","endTime":"0","summary":"0815 GMT - Novartis's decision to suspend several clinical trials for a cell therapy after three patients died is expected to have a limited financial impact, Citi analysts say in a research note. Pending further updates, the news reduces the likelihood that the Swiss drugmaker's next-generation cell-therapy platform--which aims to accelerate the process of T-cell expansion to treat autoimmune diseases--could provide a future boost, the analysts say. However, the treatment was still in midstage trials, and Citi's current peak sales estimate stands at only $440 million. Novartis shares fall 0.6%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4588","BK4585","PPH","BK4578","LU0211331839.USD","IE0002141913.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0208291251.USD","LU0070302665.USD","IE00BFTCPJ56.SGD","MEDX","BK4532","IE0009355771.USD","LU0320765489.SGD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664999869","title":"Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2664999869","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664999869?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:35","pubTimestamp":1788294900,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  rallied 2.45% to $149.92 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index  falling 0.71% to 7,631.47 and Dow Jones Industrial Average  falling 0.79% to 52,766.88.This was the stock's second consecutive day of gains.Gilead Sciences Inc. closed 4.69% short of its 52-week high of $157.29, which the company reached on February 11th.The stock outperformed some of its competitors Tuesday, as Johnson & Johnson  rose 2.01% to $271.19, Pfizer Inc.  rose 0.32% to $28.55, and Abbott Laboratories  fell 1.30% to $108.93.Trading volume  remained 2.1 million below its 50-day average volume of 6.9 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 1, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0965509283.SGD","LU1674673428.USD","BK4583","LU1571399168.USD","TBXU","BBH","LU0965509101.SGD","LU2324357040.USD","BK4568","IE0002270589.USD","SG9999015952.SGD","SG9999015986.USD","LU0889565916.HKD","LU2468319806.SGD","BK4532","IBB","LU1066051498.USD","BK4585","LU0859254822.USD","BK4578","IE00BSNM7G36.USD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU1934455194.USD","LU1934455863.HKD","LU2087621335.USD","LU0882574055.USD","MEDI","BMED","GILD","LU1061106388.HKD","SG9999015945.SGD","LU0234570918.USD","LU0965509010.AUD","LU0965508806.USD","LU2357627491.SGD","LU1839511570.USD","LU1934455277.USD","IE00BZ1G4Q59.USD","LU1037948541.HKD","LU1066053197.SGD","IE00B19Z3B42.SGD","LU2112291526.USD","LU0109394709.USD","LU1037948897.HKD","LU1430594728.SGD","BK4139","IE00B19Z3581.USD","LU0823416689.USD","LU1023059063.AUD","IBBQ","LU1585245621.USD","BK4588","LU0114720955.EUR","LU2089984988.USD","TMED","IE00B3T34201.USD","LU1674673691.USD","LU0861579265.USD","LU1778281490.HKD","LU0320765992.SGD","SG9999015978.USD","BK4550","BIB","BK4566","LU0122379950.USD","LU0058720904.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664850457","title":"H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi","url":"https://stock-news.laohu8.com/highlight/detail?id=2664850457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664850457?lang=en_us&edition=fundamental","pubTime":"2026-09-01 23:35","pubTimestamp":1788276922,"startTime":"0","endTime":"0","summary":"After Novartis (NVS) announced topline data from the REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis, H.C. Wainwright analyst E...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-says-novartis-success-in-rms-trials-does-not-impact-tgs-briumvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-says-novartis-success-in-rms-trials-does-not-impact-tgs-briumvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IE0002141913.USD","BK4532","IE00BJJMRZ35.SGD","NVS","BK4588","IE00B2B36J28.USD","IE00B4R5TH58.HKD","PPH","BK4578","MEDX","IE00BFTCPJ56.SGD","LU0208291251.USD","LU0320765489.SGD","IE00BJT1NW94.SGD","LU0070302665.USD","BK4007","IE0009355771.USD","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664527668","title":"Novartis MS Trials Open Door to Multibillion-Dollar Sales Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2664527668","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664527668?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:27","pubTimestamp":1788272820,"startTime":"0","endTime":"0","summary":"1427 GMT - Novartis's latest trial results for a multiple sclerosis drug suggest a multibillion-dollar sales opportunity is within the Swiss drugmaker's reach, analysts at J.P. Morgan say in a research note. The results for Novartis's Rhapsido reduce risk on a sales opportunity of at least $2 billion to $3 billion in relapsing multiple sclerosis alone, according to JPM. Given that consensus forecasts for 2030 sales from the drug currently stand at $3.4 billion, mainly from skin conditions, consensus estimates could see significant upgrades after the results, the analysts say. That said, detailed data are required to assess the drug's potential relative to Roche's fenebrutinib and so-called anti-CD20 therapies, a different class of medicines, they add. Novartis shares jump 6.3%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0211331839.USD","BK4532","BK4578","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0070302665.USD","NVS","LU0320765489.SGD","PPH","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","MEDX","BK4007","BK4585","LU0208291251.USD","IE0002141913.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664852288","title":"Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2664852288","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664852288?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:17","pubTimestamp":1788272261,"startTime":"0","endTime":"0","summary":"Novartis ($NVS) stock rose about 6% at the time of writing on Tuesday, after the Swiss drugmaker reported positive results from two late-stage tria...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/novartis-stock-nvs-pops-as-multiple-sclerosis-drug-shows-positive-results-in-late-stage-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/novartis-stock-nvs-pops-as-multiple-sclerosis-drug-shows-positive-results-in-late-stage-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","IE00B4R5TH58.HKD","BK4007","LU0070302665.USD","LU0208291251.USD","BK4588","LU0320765489.SGD","IE00BFTCPJ56.SGD","PPH","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4578","IE00B2B36J28.USD","IE0009355771.USD","LU0211331839.USD","IE00BJT1NW94.SGD","NVS","BK4585","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664785240","title":"Novartis AG Stock (NVS) Moved Up by 6.54% on Sep 1: Drivers Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2664785240","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664785240?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:15","pubTimestamp":1788272126,"startTime":"0","endTime":"0","summary":"• Remibrutinib succeeded in Phase III multiple sclerosis trials, showing clinical superiority.\n• Novartis paused eight early-stage CAR-T trials following three patient deaths.\n• The company reports $56.33B annual revenue and $13.98B net profit.","market":"sh","thumbnail":"https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262144163-market-movers-nvs-20260901","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","BK4578","IE0002141913.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU0211331839.USD","LU0070302665.USD","LU0320765489.SGD","MEDX","BK4588","IE00B2B36J28.USD","BK4532","BK4007","IE00BJJMRZ35.SGD","LU0208291251.USD","BK4585","NVS","IE00BFTCPJ56.SGD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664150852","title":"Novartis's Multiple Sclerosis Trial Results Match Best Hopes","url":"https://stock-news.laohu8.com/highlight/detail?id=2664150852","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664150852?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:14","pubTimestamp":1788272040,"startTime":"0","endTime":"0","summary":"1414 GMT - Novartis's trial results for a multiple sclerosis drug are in line with a blue-sky scenario, UBS analysts say in a research note. The Swiss drugmaker's results from two late-stage studies point to a greater reduction in annualized relapse rates with its Rhapsido compared to Sanofi's Aubagio, with no liver safety issues, the analysts say. These results suggest Novartis's drug might be at least a best-in-class oral medicine for the disease, according to UBS. UBS estimates that there's a 50% probability the drug's sales for relapsing multiple sclerosis reach $4.5 billion. Novartis shares jump 6.2%.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0205193047.USD","LU0208291251.USD","BK4532","LU0320765489.SGD","LU0211331839.USD","BK4007","IE00BJJMRZ35.SGD","BK4077","BK4508","IE0009355771.USD","IE0034235071.USD","BK4118","NVS","BK4549","LU0205194284.USD","IE0002141913.USD","BK4585","LU0240878834.USD","LU0070302665.USD","PPH","BK4534","LU1863844665.USD","MTCH","IE00B2B36J28.USD","BK4578","IE00B4R5TH58.HKD","LU1829250122.USD","UBS","MEDX","LU3187612489.SGD","IE00BFTCPJ56.SGD","LU0240877869.USD","IE00BJT1NW94.SGD","LU1863844749.USD","SOCL","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148610163","title":"US Stock Alert: Novartis Gains 5% On Positive Late-Stage Trial Results For MS Oral Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1148610163","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148610163?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:00","pubTimestamp":1788271219,"startTime":"0","endTime":"0","summary":"On Tuesday, shares of Novartis AG (NVS.US) climbed more than 5% to trade at $160.82 apiece. The surge follows the company's announcement that its investigational oral therapy, remibrutinib, met key...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK4007","PPH","LU0211331839.USD","IE00BJT1NW94.SGD","BK4578","LU0320765489.SGD","BK4585","IE00BFTCPJ56.SGD","01477","LU0070302665.USD","BK1574","BK4588","IE00B2B36J28.USD","BK4532","IE0009355771.USD","NVS","MEDX","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00B4R5TH58.HKD","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664485406","title":"Novartis up Nearly 6%, on Pace for Largest Percent Increase Since March 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2664485406","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664485406?lang=en_us&edition=fundamental","pubTime":"2026-09-01 21:54","pubTimestamp":1788270840,"startTime":"0","endTime":"0","summary":"Novartis AG Sponsored ADR  is currently at $160.98, up $8.92 or 5.87%--Would be highest close since March 10, 2026, when it closed at $161.59--On pace for largest percent increase since March 27, 2023, when it rose 8%--Snaps a four day losing streak--Up 16.76% year-to-date--Down 4.53% from its all-time closing high of $168.62 on Feb. 27, 2026--Up 27.12% from 52 weeks ago , when it closed at $126.64--Down 4.53% from its 52-week closing high of $168.62 on Feb. 27, 2026--Up 32.17% from its 52-week closing low of $121.80 on Oct. 29, 2025--Traded as high as $163.57; highest intraday level since March 4, 2026, when it hit $165.69--Up 7.57% at today's intraday high; largest intraday percent increase since March 27, 2023, when it rose as much as 8.37%All data as of 9:52:05 AM ETSource: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MEDX","IE00B4R5TH58.HKD","NVS","IE00BJT1NW94.SGD","LU0070302665.USD","BK4007","IE00B2B36J28.USD","PPH","IE0002141913.USD","LU0320765489.SGD","IE00BFTCPJ56.SGD","BK4578","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4532","LU0211331839.USD","BK4585","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664859859","title":"【US Pre-Market】US Futures and Chip Stocks Fall as Global Bond Sell-Off Deepens; Gold Drops Below $4,400, Brent Crude Tops $92","url":"https://stock-news.laohu8.com/highlight/detail?id=2664859859","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664859859?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:01","pubTimestamp":1788264098,"startTime":"0","endTime":"0","summary":"TradingKey - On Tuesday (September 1) Eastern Time, futures on the three major U.S. stock indexes fell across the board in pre-market trading. Geopolitical risks escalated sharply after two supertankers were hit by unidentified projectiles in the Strait of Hormuz, driving international oil prices further up. Meanwhile, the global bond market sell-off persisted, pushing long-term government bond yields in major economies to multi-year highs and significantly dampening market risk appetite.","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20240105/eb0f4a7f5f55ac405df7e752c6038bc8.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20240105/eb0f4a7f5f55ac405df7e752c6038bc8.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/analysis/stocks/us-stocks/262143844-us-pre-market-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0994945656.USD","SG9999014898.SGD","IE0002141913.USD","LU2168564495.EUR","HUTG","LU0882574139.USD","LU1037948897.HKD","IE00B3SWFQ91.USD","LU1623119135.USD","NVDG","LU1202635105.USD","LU0823414478.USD","LU2077746001.SGD","TSLZ","LU0494093205.USD","LU0106261372.USD","LU0949170772.SGD","SOXX","LU2473716301.USD","SGXZ99366536.SGD","BK4561","NVDS.UK","BK4534","CNAV","TSLG","SKUU","07366","IE00BFSS8Q28.SGD","BK4533","LU0642271901.SGD","LU0124676726.USD","LU2237443549.SGD","LU0312595415.SGD","IE00B4YYXB79.USD","LU1983260115.SGD","LU1548497426.USD","LU1084165304.USD","ANV","LU0006306889.USD","LU1868836914.USD","LU2065171311.SGD","LU2413666426.HKD","PSWD","IE00B775SV38.USD","LU2361044865.SGD","IE00BKVL7J92.USD","LU0057025933.USD","STSLAmain","LU2592432038.USD","GGLS","LU0157215616.USD","QCMD","WDCX","LU1232071149.USD","ROM","SQCOMmain","SMH","LU1823568750.SGD","LU2322448791.USD","DIPS","IE00BJTD4V19.USD","SKHYV","BK4555","LU2357627491.SGD","LU2896262040.SGD","TSLQ","LU0545039389.USD","DRMY","LU1720051108.HKD","LU1894683264.USD","LU0689472784.USD","FTEC","LU0109391861.USD","TRUC","TSLY","PTF","IE0004445015.USD","LU0302445910.USD","LU0466842654.USD","LU2092937148.SGD","AIFD","BK4579","LU0128525689.USD","IE00BJT1NW94.SGD","IE00B19Z8W00.USD","LU0170899867.USD","XNTK","LU0477156953.USD","04335","IE00BJJMRY28.SGD","VGT","LU0240878834.USD","IE00BN29S564.USD","LU2458330243.SGD","BK4529","LU0149725797.USD","HK0000914660.USD","LU0738911758.USD","LU1435385759.SGD","SINTCmain","LU2237957811.SGD","FCOM","LU2237957902.USD","LU0965509283.SGD","BK4592","LU1235294995.USD","LU1778281490.HKD","LU0690374615.EUR","LU1145028129.USD","LU0979878070.USD","LU2362541273.HKD","LU1430594728.SGD","EMSF","LU0889565833.HKD","LU1989764664.SGD","LU0353189763.USD","LU2931357623.SGD","LU1066051498.USD","LU1121112475.USD","LU1032955483.USD","HK0000320223.HKD","BK4578","SNDK","LU2430703095.HKD","LU0823397103.USD","TSLS","SKHZ","IE00BJJMRX11.SGD","09766","BUG","LU0784385840.USD","IE00BFMHRM44.USD","LU0823397285.USD","LU0345768153.USD","MIC","DELL","IE00BDCRKT87.USD","LU0345774631.USD","LU0054578231.USD","LU0477156797.USD","LU2089284900.SGD","LU1992135472.HKD","LU2065171402.SGD","LU2148611432.USD","LU0985320562.USD","LU1323610961.USD","LU2720916845.USD","LU1861127337.USD","THMR","IE000SO60NU8.SGD","SOXY","IE000MB6IJN5.SGD","LU0256863902.USD","LU2764263203.CNY","LU0061474960.USD","07788","BK4598","LU0432979614.USD","LU0708994859.HKD","LU0784384876.USD","LU2394011477.USD","IE00B1BXHZ80.USD","LU1003077747.HKD","LU2168563687.JPY","LU0980610538.SGD","TTXU","LU0225283273.USD","LU0444971666.USD","LU2125909759.SGD","BK4550","LU1670756490.USD","LU0048584097.USD","NVDU","LU0310800379.SGD","GOOY","LU1956131251.USD","IE00B4JS1V06.HKD","LU0289961442.SGD","LU2102340556.USD","LU2125154778.USD","LU0323239441.USD","SGXZ80539844.SGD","CRSH","BK4560","LU2417539215.USD","LU0061474705.USD","LU0203345920.USD","LU0210536198.USD","LU2362540622.SGD","NVDQ","LU2191332357.HKD","HK0000914686.HKD","LU2098885051.SGD","LU0175139822.USD","BK4553","IE0004086264.USD","TDV","LU1551013425.SGD","SPTE","PANG","LU0234572021.USD","LU0511384066.AUD","BK4612","3NVD.UK","LU0784385170.HKD","LU2063271972.USD","GB00B4LPDJ14.GBP","FSMD","LU1935042215.USD","EFIV","LU1821325948.USD","LU2403377893.USD","SG9999002232.USD","LU2347655156.SGD","LU0251132253.USD","LU2133065610.SGD","AIS","IE00BGHQDM52.EUR","LU0347712357.USD","LU0964807845.USD","TLA","LU1923623000.USD","LU1267930813.SGD","IE0034235303.USD","IE00BGHQF631.EUR","BK4575","TRFK","LU0345769128.USD","07766","LU1629891620.HKD","BK4605","GOOP","LU0130518102.USD","LU1861559042.SGD","LU0174119429.USD","LU1868837136.USD","LU0323591593.USD","LU0342679015.USD","XDAT","07388","BK4581","IE00BMPRXR70.SGD","LU2023251221.USD","LU2272731782.SGD","HK0000532082.HKD","LU1917777945.USD","LU2168564065.EUR","LU1506573853.SGD","LU2083900584.USD","LU0211327993.USD","SNDC","LU2250418816.HKD","LU1868836591.USD","LU2360106780.USD","CHAT","IE000BZT7R73.USD","GOGL","IE00B5TLWC47.USD","LU0553294199.USD","LU1061106388.HKD","LU1989771016.USD","LU2552382215.SGD","PSI","LU2168564222.USD","LU1670627923.USD","MRVU","LU2456880835.USD","LU0211326839.USD","LU0203202063.USD","GGLL","LU0082616367.USD","LU1221951046.USD","IE00BVYPNW00.USD","SKHL","LU0957808578.USD","LU1815333072.USD","IE000Q6AESB8.SGD","LU2125909916.SGD","LU1244550494.USD","NVDO","HK0000306701.USD","INTW","LU1923622614.USD","TSLI","LU0211326755.USD","LU2433249047.HKD","BK4600","LU2242649171.HKD","LU2294711713.HKD","LU1894683348.USD","CNEQ","LU0048573561.USD","LU1861558580.USD","LU1992135399.USD","LU2237438978.USD","LU1791710400.SGD","LU1935043023.USD","LU0211328371.USD","LU0154236417.USD","LU0210533765.USD","LU0345774391.USD","LU0820561818.USD","GOOGL","BK4023","NVD","LU0158827781.USD","HK0000304805.HKD","MUU","IE00BJJMRZ35.SGD","LU2244417387.USD","SG9999018857.SGD","07709","MDT","IE00BJLML261.HKD","SCHA","GPRO","LU0957791311.USD","IE00B1XK9C88.USD","LU0426417589.USD","IE00B2B36J28.USD","LU0965509101.SGD","GB00B4QBRK32.GBP","LU2087621335.USD","IE0001KFT4U8.USD","LU0949170426.SGD","LU0528227936.USD","LU0859254822.USD","LU2764262908.HKD","IE00BMPRXQ63.HKD","LU0786609619.USD","LU2463028550.USD","LU2092627202.USD","LU2272731600.USD","LU1914381329.SGD","LU1267930730.SGD","SK","LU0006061336.USD","LU0792757196.USD","LU2290526834.HKD","LU0868494708.USD","LU1046421795.USD","NVDL","QQQA","LU1496350171.SGD","SGXZ31699556.SGD","CHPX","LU0314106906.USD","LU2095319765.USD","LU1699723380.USD","LU1291159041.SGD","LU0080751232.USD","HK0000306685.HKD","IE00BWXC8680.SGD","PALU","IGV","LU0240877869.USD","LU0795875169.SGD","LU0787776722.HKD","BK4595","LU0251142724.SGD","LU0310799852.SGD","LU0708995401.HKD","LU2249611893.SGD","LU0820562030.AUD","LU0321505868.SGD","LU0210528500.USD","ELOL","LU1116320737.USD","SGXZ81514606.USD","HK0000320264.USD","NVYY","IE00BZ1G4Q59.USD","LU0823421416.USD","LU1144417596.USD","LU2461242641.AUD","SG9999015978.USD","SNPE","TSLP","NVC","LU1037948541.HKD","LU0861579265.USD","LU1064131342.USD","LU1989764748.USD","LU0274383776.USD","BK4566","LU1066051225.USD","LU2326559502.SGD","SG9999015986.USD","LU2065169927.USD","SMHX","XLC","AGOX","LU1852331112.SGD","SG9999014542.SGD","BK4514","IE00B5949003.HKD","VOX","IE00B19Z9505.USD","LU1935042991.SGD","LU1839511570.USD","LU1935043536.SGD","QCMU","LU0726765562.USD","SNDU","LU0143551892.USD","IE00B3S45H60.SGD","LU1069344957.HKD","LU0096364046.USD","MU","SKHX","ESUM","LU1645745479.HKD","LU2357125470.USD","SG9999001424.SGD","LU1633808545.USD","LFGY","LU2211815571.USD","SHOC","BK4548","LU0215105999.USD","LU0276348264.USD","VT","LU0661504455.SGD","LU0823411888.USD","LU2089985449.USD","LU0444973449.USD","LU1712237335.SGD","LU2756315318.SGD","LU1983299246.USD","LU2100268510.USD","LU2264538146.SGD","CGGO","IE0003U64NQ7.SGD","LU0096362180.USD","LU2087625088.SGD","LU1803068979.SGD","IDRV","IE00BFSS7M15.SGD","LU1674673428.USD","LU2462591277.SGD","LU2756315664.SGD","SG9999014575.USD","RULE","LU1732799900.SGD","LU0795875086.SGD","LU1043141396.HKD","IE00BK4W5L77.USD","LU2089283258.USD","LU2361045086.USD","LU0251131958.USD","LU2404859741.USD","IXN","QQQG","LU2275660780.HKD","LU0320765489.SGD","LU0690374961.EUR","LU2065170008.USD","BK4608","TSII","IE00BZ199S13.USD","LU2097344357.USD","LU0345769631.USD","LU0203347892.USD","CIBR","IE00B3M56506.USD","LU2462157665.USD","LU2125154935.USD","IE0009355771.USD","LU0345770993.USD","AIQ","LU2491050154.USD","LU2210149790.SGD","IE000KEQY171.SGD","QCML","LU2505996509.AUD","LU1267930227.SGD","LU0321505439.SGD","CLSE","LU0742534661.SGD","LU1116320901.HKD","LU0963586101.USD","NVII","IE00BLSP4452.SGD","LU1974910355.USD","LU0267386448.USD","NVDY","BK4516","BK4549","HK0000304797.USD","IHAK","LU0689626769.HKD","LU0130102774.USD","BK4574","TMSL","LU0823413660.USD","LU2108987350.USD","LU2750360997.AUD","LU1066051811.HKD","LU1791710582.SGD","HAKY","SG9999000418.SGD","TSLO","LU1267930573.SGD","GB00BDT5M118.USD","OGIG","LU0133085943.USD","IE00BKPKM429.USD","LU1718418525.SGD","LU2112291526.USD","TSYY","LU1861220033.SGD","SKHY","LU0097036916.USD","LU1732800096.USD","IE00B7KXQ091.USD","LU1989772923.USD","LU2237443978.SGD","SGXZ44715902.SGD","LU2506951792.HKD","IE00BDRTCR15.USD","NVDA","BAI","SKHA","XLK","LU1035775433.USD","LU0234570918.USD","LU0265550359.USD","LU1988902786.USD","LU2750360641.GBP","BK4573","IE0009G5SDU7.USD","LU0472753341.HKD","AIPI","IE00B775H168.HKD","TEK","TSLW","OPTZ","LU0648001328.SGD","LU1303367103.USD","WLDR","IE00BMPRXN33.USD","LU2028103732.USD","WCLD","LU0130517989.USD","GOOX","IE0002270589.USD","TESL","NVDW","LU2089984988.USD","HYNX","ESLG","WCBR","LU0072461881.USD","BK4535","LU1023059063.AUD","HBMX","LU0011850046.USD","LU2023250843.SGD","LU3102509885.SGD","BK4551","LU2746668461.USD","MUYY","LU0640476718.USD","LU2458330169.SGD","TYLG","LU1721428933.USD","LU0056508442.USD","LU2602419157.SGD","SNDG","DLLL","LU2242650005.HKD","SMU00main","LU0788109477.HKD","IE00BHPRN162.USD","LU2054465674.USD","LU2237443622.USD","LU1815336760.USD","DRIV","LU0070302665.USD","BK4007","NVD2.UK","FCUS","MNRS","LU1366192091.USD","LU1059921491.USD","ARTY","LU1571399168.USD","NULC","LU1201861249.SGD","LU0130103400.USD","NVDX","LU1934455863.HKD","LU1803068623.USD","LU0320765059.SGD","SG9999015358.SGD","IE000YTNTUN2.SGD","LINT","LU2272731865.HKD","SGXZ51526630.SGD","CQTM","CMAG","IE00B19Z3B42.SGD","LU0266013472.USD","LU0426412945.USD","BK4512","LU2023250330.USD","LU2247934214.USD","LU0345770308.USD","LU0868494617.USD","CLOD","BK4532","IE00BD6J9T35.USD","FDTX","BK4170","LU2491050071.SGD","WDC","BK4588","LU2471134952.CNY","IE00BN8TJ469.HKD","IE00BQXX3D17.EUR","IE00BVYPNP33.GBP","USXF","IE00BJTD4N35.SGD","LU1642822529.SGD","LU2048586759.USD","LU1316542783.SGD","SG9999017495.SGD","BK4554","NVDD","LU2125909247.SGD","LU2097344431.USD","LTL","BK4141","LU1814569148.SGD","LU0138981039.USD","MEDX","TSLT","FDRV","LU2552382132.HKD","IE00B19Z8X17.USD","LU1261432733.SGD","TSLA","BK4614","LU2265009873.SGD","IE00BQXX3C00.GBP","INT","LU1153585028.USD","NVDB","FTXL","LU1035773651.USD","LU2413666699.HKD","MRVL","LEGR","NVIW.SI","LU1221951129.SGD","TSLL","LU0823413587.USD","SNXX","DTCR","BK4515","NVD3.UK","LU2764263039.SGD","LU1301847155.USD","LU1057294990.SGD","GTEK","IE0005OL40V9.USD","LU0203201768.USD","LU0354030511.USD","LU2420271590.USD","LU1366333091.USD","LU1551013342.USD","GXPC","TTEQ","LU2468319806.SGD","FXL","SG9999018865.SGD","IE0034235188.USD","LU0820561909.HKD","LU0158827948.USD","LU0496365809.HKD","LU0316494557.USD","LU2168564149.EUR","FAI","LU2430703251.USD","LU0823414551.USD","LU0053666078.USD","LU0162691827.USD","LU0912757837.SGD","IE00BFTCPJ56.SGD","LU0308772762.SGD","USD","BK4567","IE0004091025.USD","LU0353189680.USD","LU1496350502.SGD","IE000ITXATA3.USD","LU1670628061.USD","MRVX","SGXZ23171101.USD","SG9999014914.USD","LU2543165471.USD","LU0823434583.USD","LU0557290698.USD","IETC","LU1267930490.SGD","HUT","LU0889566641.SGD","SG9999014880.SGD","NVDS","IE00BBT3K403.USD","IE000F7OJYX1.SGD","LU1674673691.USD","LU1400636574.HKD","LU0069063385.USD","LU0672654240.SGD","BK4604","SKHU","PALD","IE0004445239.USD","MUG","BLCK","BK4099","LU0070217475.USD","LU2430703178.SGD","TSL","LU2462591350.SGD","BK4077","SG9999014567.USD","LU0348723411.USD","SG9999014906.USD","LU0077335932.USD","LU2505996681.GBP","SNVD.UK","LU1989772840.SGD","LU0314104364.USD","LU1196500208.SGD","SKDD","SPAM","LU1169590202.USD","IE000WAW04H5.SGD","LU2471134523.USD","LU1868837300.USD","BK4511","IE000W1ABFV2.USD","LU0256863811.USD","LU2954938101.SGD","LU2999663052.SGD","LU2237443895.HKD","BK4078","HK0000819398.USD","CHPS","LU1400636657.SGD","SNVDAmain","EGGY","IE0000B7K699.USD","LU0061475181.USD","LU2471134796.USD","LU0289739343.SGD","LU2286300806.USD","SG9999015952.SGD","LU2357305700.SGD","BK4587","IE0034235295.USD","BK4503","SG9999004303.SGD","LU2552382058.USD","BK4097","LU2097829019.USD","TSLR","LU0211331839.USD","COWG","LU1880398471.USD","MULL","LU1979441026.SGD","LU0029864427.USD","GAMR","LU1861215975.USD","BK4543","LU0094547139.USD","LU1923622291.USD","INTC","LU0109392836.USD","BK4585","LU0079474960.USD","LU1935042488.USD","LU1119994496.HKD","LU2491049909.HKD","GOU","LU1069347547.HKD","LU1280957306.USD","SNDQ","LU2860962120.EUR","LU2047632596.USD","BOBP","LU0395794307.EUR","SCHM","LU1804176565.USD","IE00B4R5TH58.HKD","LU2355687059.USD","TSDD","INYY","LU0943347566.SGD","LU0976567544.SGD","LU0072462426.USD","LU2381873111.SGD","SG9999015945.SGD","METV","LU0648000940.SGD","ILDR","LU0128525929.USD","LU2023250504.SGD","LU2271345857.HKD","QCOM","LU2487616109.SGD","IE00BLSP4239.USD","IE00BVYPNV92.GBP","LU0724617625.USD","SOXQ","GOOL","LU0784383803.USD","LU2746668974.SGD","LU0127658192.USD","LU2347655073.USD","LU0345768740.USD","SG9999002224.SGD","WISE","IE0009356076.USD","LU0390134368.USD","LU2106854487.HKD","LU2637965513.SGD","BK4082","IE00BKDWB100.SGD","LU0107464264.USD","NVS","LU1244550577.SGD","LU1934455194.USD","LU1201861165.SGD","IE000M9KFDE8.USD","BK4538","LU2360107168.USD","LU1242518931.SGD","LU1880398554.USD","09388","BK4602","LU1868836757.USD","LU1934455277.USD","SKYY","LU0187121727.USD","LU1400636491.USD","LU1691799644.USD","09788","LU2279689827.SGD","LU2404859667.USD","LU0289960550.SGD","IE00B3T34201.USD","LU0198837287.USD","WUGI","MUZ","LU0310800965.SGD","LU2322448957.HKD","TEST","MUD","TESC","IE00B7SZLL34.SGD","PANW","LU0823421333.USD","LU1066053197.SGD","LU0965509010.AUD","LU2236285917.USD","LU2111349929.HKD","LIT","LU2361044949.HKD","LU2213496289.HKD","LU2471134879.HKD","LU0122379950.USD","MVLL","2NVD.UK","LU0265550946.USD","LU2210150020.SGD","BK4527","GOOW","ABFL","IE00B42XCP33.USD","DISK","LU0354030438.USD","LU0942090050.USD","LU1043141123.HKD","LU1951198990.SGD","IE00BFXG1179.USD","WANT","IE00B3PB1722.GBP","LU0719512351.SGD","LU2237443382.USD","LU1951200564.SGD","LU1429558221.USD","LU0081259029.USD","LU0238689110.USD","LU1244550221.USD","PPH","LU0052756011.USD","IE00B19Z3581.USD","LU1127390331.HKD","SKHN","LU0323240290.USD","BK4576","LU0208291251.USD","LU2360032135.SGD","SG9999014559.SGD","IE00BQXX3F31.USD","IE00BK4W5M84.HKD","WATS","LU2452424414.USD","IE00BVYPNQ40.USD","IE00BYXW3230.USD","LU0476273544.USD","SMOG","LU1169589451.USD","IE00BDGV0183.EUR","IE00BSNM7G36.USD","LU0417517546.SGD","LU0683600562.USD","LU1720051017.SGD","LU0965508806.USD","LU2125909593.SGD","09366","SG9999015341.SGD","LU0823434740.USD","JGRO","LU2237443465.HKD","WDCC","LU2362541513.USD","LU1242518857.USD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664568448","title":"Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2664568448","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664568448?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:49","pubTimestamp":1788263354,"startTime":"0","endTime":"0","summary":"FACTBOX-Global pharma companies that have publicly announced Trump drug pricing agreementsSept 1 (Reuters)-U.S. President Donald Trump has struck drug-pricing deals with more than 20 pharmaceutical co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4N44T0TS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000BZT7R73.USD","BMY","IE00BKVL7J92.USD","LU2111349929.HKD","LU1894683348.USD","LU1221951046.USD","LU1718418525.SGD","LU2087625088.SGD","IE00BLSP4452.SGD","LU1074936037.SGD","LU2403377893.USD","SG9999018865.SGD","SG9999017495.SGD","NVS","LU2108987350.USD","LU2552382132.HKD","LU1066053197.SGD","LU2471134952.CNY","LU2360106947.USD","LU0661504455.SGD","LU1989772923.USD","LU1712237335.SGD","SG9999014914.USD","LU0072461881.USD","LU2756315318.SGD","LU1988902786.USD","BK4533","LU0124676726.USD","BK4588","LU2028103732.USD","LU2347655156.SGD","BK7067","MEDI","LU0238689110.USD","IE0002141913.USD","LU0154236417.USD","LU0321505439.SGD","LU1974910355.USD","LU0943347566.SGD","NVO","LU1059921491.USD","IE00B4R5TH58.HKD","LU1201861249.SGD","IE00B4JS1V06.HKD","IE00BFXG1179.USD","LU2023250843.SGD","04332","LU1232071149.USD","LU0158827781.USD","LU0162691827.USD","LU0234572021.USD","IE00BK4W5L77.USD","LU1267930490.SGD","SG9999014880.SGD","SG9999014559.SGD","IE00B19Z3581.USD","LU1116320737.USD","IE00BKPKM429.USD","BK4585","LU0965509101.SGD","LU1127390331.HKD","HRTS","LU0417517546.SGD","IE00BFSS8Q28.SGD","BMED","LU0345769631.USD","LU0994945656.USD","LU0787776722.HKD","LU0511384066.AUD","IE000MB6IJN5.SGD","LU1228905540.USD","LU1868837300.USD","LU2087621335.USD","LU2133065610.SGD","SGXZ31699556.SGD","IBB","LU0949170772.SGD","LU2324357040.USD","LU1979441026.SGD","LU2360032135.SGD","AZN","LU1066051225.USD","BK4566","IE000SO60NU8.SGD","LU1244550221.USD","LU0965508806.USD","LU1778281490.HKD","LU0306806265.USD","IE00BVYPNW00.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0545562505.USD","IE000F7OJYX1.SGD","SGXZ99366536.SGD","SG9999014542.SGD","IE0009355771.USD","LU1267930813.SGD","BIB","LU0203347892.USD","XLV","LU0256863811.USD","RXL","GSK","LU0109394709.USD","LU2362541273.HKD","SGXZ80539844.SGD","LU2596442595.SGD","SGXZ57979304.SGD","LU2750360641.GBP","SG9999011175.SGD","SG9999015358.SGD","LU1280957306.USD","IE00B7SZLL34.SGD","LU0094547139.USD","LU0820561909.HKD","PFE","LU0158827948.USD","LU0708995401.HKD","LU1868837136.USD","IE0000B7K699.USD","LU0079474960.USD","LU1035775433.USD","LU0738911758.USD","SG9999002224.SGD","LU0316494557.USD","LU0267386448.USD","LU0882574055.USD","LU0640476718.USD","LU0820562030.AUD","LU1804176565.USD","BK4599","LU0320765489.SGD","LU1244550577.SGD","BBH","LU2357627491.SGD","LU0868494708.USD","MRK","LU1674673428.USD","NVOC","IE00BN8TJ469.HKD","LU0097036916.USD","LU0354030438.USD","LU2125909593.SGD","LU1720051108.HKD","LU0170899867.USD","LU0964807845.USD","LU0820561818.USD","LU1037948897.HKD","NVOH","LU2211815571.USD","LU1066051811.HKD","LU1732799900.SGD","LU2112291526.USD","LU2462157665.USD","LU1093756168.USD","LU0061475181.USD","LU0689626769.HKD","LU0320765646.SGD","IE00BJLML261.HKD","LU0211327993.USD","LU2347655073.USD","BK4516","LU0912757837.SGD","LU1366192091.USD","LU2505996681.GBP","SG9999014575.USD","LU0310799852.SGD","LU2264538146.SGD","IE00B2B36J28.USD","LU1023059063.AUD","LU1003077747.HKD","LU0965509283.SGD","LU0211331839.USD","LU1496350171.SGD","LU1670710661.SGD","FHLC","LU1066051498.USD","THNR","LU1196500208.SGD","LU1244550494.USD","LU0225771236.USD","FTXH","MHIP","IE00BFSS7M15.SGD","LU0265550946.USD","CURE","LU1093756325.SGD","LU1670710588.SGD","LU2461242641.AUD","LU1868836914.USD","LU2491050071.SGD","LU0795875169.SGD","LU1228905037.USD","LU1934455194.USD","LU1267930730.SGD","BK0239","REGN","LU0466842654.USD","LU0859254822.USD","LU2468319806.SGD","BK4007","LU0234570918.USD","IE00BJJMRX11.SGD","LU2023251221.USD","LU1064131342.USD","LU1914381329.SGD","LU2237438978.USD","LU0069063385.USD","LU0889566641.SGD","LU0553294199.USD","LU2756315664.SGD","GILD","IE0004445239.USD","LU0174119429.USD","LU1670711040.USD","LU1236620834.HKD","LU1989771016.USD","LU0868494617.USD","IXJ","TRUH","LU1236620750.USD","LU2487616109.SGD","AZNH","LU0889565916.HKD","LU1116320901.HKD","IE0004445015.USD","IE00BVYPNV92.GBP","LU0708994859.HKD","IE00B7KXQ091.USD","IE0034235303.USD","LU1934455277.USD","LU0471298694.HKD","LU2089283258.USD","LU0130517989.USD","AMGN","LU1670711123.USD","LU1043141396.HKD","LU0029864427.USD","LU1551013342.USD","LU1670628061.USD","LU1868836591.USD","SG9999015986.USD","SG9999018857.SGD","LU0353189680.USD","LU2168564222.USD","LU1145028129.USD","SG9999013999.USD","BK4532","SG9999015952.SGD","IE000WAW04H5.SGD","IE00BWXC8680.SGD","LU0320765059.SGD","IE00BLSP4239.USD","LU2265009873.SGD","CSL.AU","BK4592","LU0980610538.SGD","LU0683600562.USD","LU2168564065.EUR","LU0114720955.EUR","LU2471134879.HKD","IYH","LU2746668974.SGD","LU1623119135.USD","AGNG","LU0130102774.USD","LU0385154629.USD","LU1221951129.SGD","GSK.UK","LU0426412945.USD","LU0823434740.USD","LU0058720904.USD","LU2746668461.USD","LU0098860793.USD","LU2462591350.SGD","LU2089984988.USD","LU0225284248.USD","LU2242652126.USD","LLY","688235","IE00B1XK9C88.USD","LU2168563687.JPY","LU1629891620.HKD","LU0471298777.SGD","LU2089284900.SGD","SG9999003800.SGD","LU1037948541.HKD","LU2552382215.SGD","BK7501","TBXU","LU1934455863.HKD","IE00BN29S564.USD","LU0006306889.USD","LU0792757196.USD","LU0823416689.USD","LU0726765562.USD","BK4504","LU1323610961.USD","LU1032955483.USD","LU2271345857.HKD","LLYX","LU1506573853.SGD","LU1057294990.SGD","IE00BZ1G4Q59.USD","LU1430594728.SGD","LU0345769128.USD","LU0942090050.USD","TMED","LU1829250122.USD","SGXZ51526630.SGD","SG9999014567.USD","06160","IE00BJJMRY28.SGD","LU1032466523.USD","LU1261432733.SGD","LU2168564149.EUR","LU2125154778.USD","LU0353189763.USD","LU0395794307.EUR","OZEM","LU2362540622.SGD","LU0070302665.USD","IE00BBT3K403.USD","LU0472753341.HKD","SG9999015945.SGD","LU0265550359.USD","LU0096364046.USD","LU0256863902.USD","LU2168564495.EUR","IHE","LU1035773651.USD","LU1069344957.HKD","LU2505996509.AUD","IE00B19Z3B42.SGD","IE00BGHQF631.EUR","LU1699723380.USD","WDNA","LU1496350502.SGD","SG9999001176.SGD","PAWZ","LU1814569148.SGD","VHT","LU1917777945.USD","LU2213496289.HKD","SG9999001176.USD","IE00B775H168.HKD","BK4139","LU0237698245.USD","SG9999014906.USD","BK4578","LU2129689605.HKD","LU2417539215.USD","GDOC","LU0672654240.SGD","LU0266013472.USD","LU1043141123.HKD","LU1989772840.SGD","LU2433249047.HKD","LU0203202063.USD","PBE","IE00B3PB1722.GBP","LU1941712264.USD","LLYZ","LU0456855351.SGD","CANC","LU0648001328.SGD","BK7508","BK7511","LU2491049909.HKD","LU1894683264.USD","LLII","LU0965509010.AUD","LU0203201768.USD","IE0001KFT4U8.USD","LU1983299246.USD","LU0128525929.USD","BBIO","LU2237443549.SGD","LU2602419157.SGD","LU2361044865.SGD","LU2357305700.SGD","LU0310800379.SGD","ELIS","IE0002270589.USD","LU1941712348.USD","LU2471134523.USD","JDOC","BK4581","GLAM","LU2592432038.USD","PJP","LU0545039389.USD","LU2129689514.USD","IE000M9KFDE8.USD","LU2125154935.USD","LU0786609619.USD","LU0861579265.USD","PPH","SG9999015978.USD","LU1691799644.USD","LU0106261372.USD","LU0795875086.SGD","LU1732800096.USD","LU1839511570.USD","LU0426417589.USD","LU1674673691.USD","LU0345770993.USD","LU2237443622.USD","LU0109391861.USD","LU2362541513.USD","SG9999002232.USD","LU2242646821.SGD","MEDX","SG9999001440.SGD","LU0070217475.USD","IE0005OL40V9.USD","LU0306807586.USD","IE00BSNM7G36.USD","ONC","LU2237443895.HKD","LU0211328371.USD","LU2430703095.HKD","LU0198837287.USD","LU2896262040.SGD","LU0203345920.USD","LU2129689431.USD","LU2456880835.USD","LU0289739343.SGD","IE00BK4W5M84.HKD","LU1121112475.USD","BK4505","IE00B42XCP33.USD","ELIL","IE00BDGV0183.EUR","LU0985320562.USD","LU0882574139.USD","IE00B3T34201.USD","LU0323591593.USD","LU1061106388.HKD","SG9999014898.SGD","IE00BKDWB100.SGD","SGXZ81514606.USD","LU0208291251.USD","NVOX","LU2750360997.AUD","LU2361044949.HKD","LU1670627923.USD","LU2361045086.USD","LU0133085943.USD","LU2430703178.SGD","ILDR","LU2471134796.USD","LU1571399168.USD","ABBV","LU1923622614.USD","BK4559","BK4550","IE00BFTCPJ56.SGD","LU0689472784.USD","LU0345770308.USD","LU0210528500.USD","LU2491050154.USD","LU0122379950.USD","JNJ","LU0985481810.HKD","LU1551013425.SGD","IBBQ","LU0477156953.USD","LU0321505868.SGD","LU0057025933.USD","LU0320765992.SGD","LU1585245621.USD","BK4583","LU1935042991.SGD","LU0354030511.USD","LU1929549753.HKD","LU2430703251.USD","LU0289961442.SGD","LU2552382058.USD","BK4568","LU0225283273.USD","LU2236285917.USD","LU0432979614.USD","LU1883839398.USD","LU1548497426.USD","GSKH","LU2023250330.USD","LU1720051017.SGD","LU2125909247.SGD","SG9999015341.SGD","LU2063271972.USD","LU2237443978.SGD","LU2237443382.USD","BK4534","LU1868836757.USD","GB00BDT5M118.USD","LU0823434583.USD","LU2023250504.SGD","LU2106854487.HKD","LU1069347547.HKD","LU0210536198.USD","LU2237443465.HKD","IE00B1BXHZ80.USD","LU0053666078.USD","LU1162221912.USD","LU1291159041.SGD","LU1267930573.SGD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855406","title":"Why Novartis Stock is Heading for Its Best Day Since 2023 After 3 Patient Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855406","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664855406?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:34","pubTimestamp":1788262440,"startTime":"0","endTime":"0","summary":"Novartis released a mixed bag of clinical updates, pausing trials for one drug after a spate of patient deaths while simultaneously revealing positive data for a pill that analysts view as a potential","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0070302665.USD","PPH","IE00BJT1NW94.SGD","BK4585","IE0002141913.USD","IE0009355771.USD","BK4532","IE00BJJMRZ35.SGD","LU0208291251.USD","IE00B4R5TH58.HKD","LU0320765489.SGD","MEDX","BK4007","IE00B2B36J28.USD","LU0211331839.USD","BK4578","IE00BFTCPJ56.SGD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664580608","title":"Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2664580608","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664580608?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:34","pubTimestamp":1788258840,"startTime":"0","endTime":"0","summary":"Novartis shares rose after the drugmaker reported positive results from two late-stage trials in the most common form of multiple sclerosis, saying its new pill helped patients experience fewer flare-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PPH","LU0211331839.USD","IE00BJT1NW94.SGD","BK4578","LU0320765489.SGD","BK4585","IE00BFTCPJ56.SGD","LU0070302665.USD","BK4588","IE00B2B36J28.USD","BK4532","IE0009355771.USD","NVS","MEDX","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00B4R5TH58.HKD","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664580128","title":"Novartis announces results from Phase III Remodel-1/-2 trials of remibrutinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2664580128","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664580128?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:30","pubTimestamp":1788258656,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced positive topline results from its Phase III Remodel-1/-2 trials of remibrutinib in relapsing multiple sclerosis. Remibruti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-announces-results-from-phase-iii-remodel-1-2-trials-of-remibrutinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-announces-results-from-phase-iii-remodel-1-2-trials-of-remibrutinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IE00BFTCPJ56.SGD","LU0320765489.SGD","NVS","LU0208291251.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00B2B36J28.USD","MEDX","LU0070302665.USD","BK4532","IE00BJT1NW94.SGD","BK4585","BK4588","LU0211331839.USD","IE0009355771.USD","BK4578","PPH","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664985383","title":"Novartis halts autoimmune CAR-T trials following three deaths, Reuters says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664985383","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664985383?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:30","pubTimestamp":1788258648,"startTime":"0","endTime":"0","summary":"Novartis (NVS) has paused eight clinical trials of rap-cel, an experimental cell therapy targeting autoimmune and neurological disorders, after thr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-halts-autoimmune-car-t-trials-following-three-deaths-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-halts-autoimmune-car-t-trials-following-three-deaths-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","GDOC","IE0002141913.USD","BK4585","LFSC","NVIB","LU0211331839.USD","IE00B2B36J28.USD","IBBQ","BMED","IBB","IE0009355771.USD","CNCR","IE00BFTCPJ56.SGD","FBT","BK4532","LU0070302665.USD","PPH","IE00BJJMRZ35.SGD","NVS","GNOM","IE00BJT1NW94.SGD","IDNA","SYNB","TBXU","LU0208291251.USD","IE00B4R5TH58.HKD","HYLG","BK4588","MEDX","LU0320765489.SGD","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664383293","title":"Novartis Says Remibrutinib Significantly Reduces Relapse Rates in Phase 3 Multiple Sclerosis Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383293","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664383293?lang=en_us&edition=fundamental","pubTime":"2026-09-01 16:51","pubTimestamp":1788252718,"startTime":"0","endTime":"0","summary":"Novartis  said Tuesday that phase 3 trials of remibrutinib showed significantly reduced annualized relapse rates compared with teriflunomide in adults with relapsing multiple sclerosis.The trials met their primary endpoints and showed that remibrutinib was superior to teriflunomide on all key secondary measures.A preplanned combined analysis also showed a positive trend in three month confirmed disability progression and nominally significant results for six month confirmed disability progression, Novartis said.Remibrutinib also demonstrated a favorable safety profile with no liver safety signal, the company said.Novartis shares were over 4% higher in Tuesday premarket activity.Price: 158.47, Change: +6.41, Percent Change: +4.22","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4578","BK4588","NVS","BK4007","LU0320765489.SGD","IE00B2B36J28.USD","IE0002141913.USD","BK4585","LU0208291251.USD","LU0070302665.USD","MEDX","PPH","LU0211331839.USD","BK4532","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132713513","title":"Novartis Faces Dual Outcomes: CAR-T Halted After Three Deaths While MS Drug Shows Late-Stage Promise","url":"https://stock-news.laohu8.com/highlight/detail?id=1132713513","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132713513?lang=en_us&edition=fundamental","pubTime":"2026-09-01 15:50","pubTimestamp":1788249011,"startTime":"0","endTime":"0","summary":"Swiss pharmaceutical giant Novartis AG (NVS.US) is experiencing a stark contrast in its neuro-immunology pipeline, as progress in one area is overshadowed by a serious setback in another. The company...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","IE0002141913.USD","BK4532","BK4585","BK1574","BK4578","PSYK","IBBJ","BMED","MDTX","PPH","IE0009355771.USD","LU0208291251.USD","MEDX","LU0320765489.SGD","IE00BJJMRZ35.SGD","LU0070302665.USD","BK1191","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4007","IE00BJT1NW94.SGD","IBBQ","BK4588","LU0211331839.USD","NVS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":105,"code":"91000000","status":"200"}]}}